Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A multinodular intermediate fibroblastic neoplasm that arises from soft tissue or viscera, in children and young adults. It is characterized by the presence of spindle-shaped fibroblasts and myofibroblasts, and a chronic inflammatory infiltrate composed of eosinophils, lymphocytes, and plasma cells.
Biomarker and diagnostic research for inflammatory myofibroblastic tumor has been reported in the published literature.
1 FDA-approved treatment is available for inflammatory myofibroblastic tumor, including CRIZOTINIB (XALKORI, approved 2011).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy and procedural interventions. Pipeline includes 1 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.
290 publications have been identified in PubMed for inflammatory myofibroblastic tumor. Kisho has analyzed 142 by research type. Research spans Case Report / Case Series (59%), Review / Meta-Analysis (21%), and Basic Science / Preclinical (5%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 84 |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 1:03 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
CRIZOTINIB |
— |
2011 |
Available |
Gene therapy approaches for inflammatory myofibroblastic tumor have been reported in the published literature.
2 trials found
59%
Research summaries | 30 | 21% |
Laboratory research | 7 | 5% |
Other research | 6 | 4% |
Testing and diagnosis research | 5 | 4% |
Disease patterns and progression | 5 | 4% |
Clinical study results | 4 | 3% |
New treatment approaches | 1 | 1% |
Khalid H (2026). [PMID: 42148360](https://pubmed.ncbi.nlm.nih.gov/42148360/). *Clin Case Rep*. [Case Report / Case Series]
Rahman Z (2026). [PMID: 42220836](https://pubmed.ncbi.nlm.nih.gov/42220836/). *Cureus*. [Case Report / Case Series]
Dumludağ A (2026). [PMID: 41549169](https://pubmed.ncbi.nlm.nih.gov/41549169/). *Sci Rep*. [Clinical Trial Publication]
Li J (2026). [PMID: 41524009](https://pubmed.ncbi.nlm.nih.gov/41524009/). *Int J Ophthalmol*. [Epidemiology / Natural History]
Arciuolo D (2026). [PMID: 41380847](https://pubmed.ncbi.nlm.nih.gov/41380847/). *Mod Pathol*. [Basic Science / Preclinical]
Akın AE (2026). [PMID: 41706176](https://pubmed.ncbi.nlm.nih.gov/41706176/). *Virchows Arch*. [Case Report / Case Series]
Liu H (2026). [PMID: 42100431](https://pubmed.ncbi.nlm.nih.gov/42100431/). *Front Oncol*. [Case Report / Case Series]
Li Y (2026). [PMID: 40607701](https://pubmed.ncbi.nlm.nih.gov/40607701/). *Cornea*. [Case Report / Case Series]
Zhang Z (2026). [PMID: 42088205](https://pubmed.ncbi.nlm.nih.gov/42088205/). *Front Oncol*. [Case Report / Case Series]
Jonuzi A (2026). [PMID: 42047068](https://pubmed.ncbi.nlm.nih.gov/42047068/). *Med Glas (Zenica)*. [Epidemiology / Natural History]
AI-curated news mentioning inflammatory myofibroblastic tumor
Updated Aug 6, 2026
A recent study published in PubMed highlights the use of FDG-PET/CT for detecting inflammatory myofibroblastic tumors in the testis, showcasing a rare presentation of this neoplasm. This research contributes to the understanding of diagnostic approaches for rare tumors.
A recent study highlights the diagnostic challenges posed by primary inflammatory myofibroblastic tumors of the breast during aspiration cytology. This research underscores the need for heightened awareness among pathologists to avoid misdiagnosis.